FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/01/079552 [Registered on: 27/01/2025] Trial Registered Prospectively
Last Modified On: 18/01/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Ayurveda
Preventive 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Effect of Haritaki with Jaggery in Summer Season on Immumity 
Scientific Title of Study   Immuno-modulatory effect of Ritu Haritaki along with Gud In healthy individual during the Greeshma Ritu – A Pilot Study  
Trial Acronym  nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Rohit Mandal 
Designation  PG Scholar Department of Swasthavritta 
Affiliation  Chaudhary Brahm Prakash Ayurved Charak Sansthan 
Address  Room no 222 PG Department of Swasthavritta Chaudhary Brahm Prakash Ayurved Charak Sansthan khera dabar Najafgarh Delhi

South West
DELHI
110073
India 
Phone  7011305749  
Fax    
Email  mandalrohit25@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prof Dr Unnikrishnan S 
Designation  Head of Department 
Affiliation  Chaudhary Brahm Prakash Ayurved Charak Sansthan 
Address  Room no 232 PG Department of Swasthavritta Chaudhary Brahm Prakash Ayurved Charak Sansthan khera dabar Najafgarh Delhi

South West
DELHI
110073
India 
Phone  9540265445  
Fax    
Email  drunnikrishnans@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Prof Dr Unnikrishnan S 
Designation  Head of Department 
Affiliation  Chaudhary Brahm Prakash Ayurved Charak Sansthan 
Address  Room no 232 PG Department of Swasthavritta Chaudhary Brahm Prakash Ayurved Charak Sansthan khera dabar Najafgarh Delhi

South West
DELHI
110073
India 
Phone  9540265445  
Fax    
Email  drunnikrishnans@gmail.com  
 
Source of Monetary or Material Support  
Chaudhary Brahm Prakash Ayurved Charak Sansthan 
 
Primary Sponsor  
Name  Chaudhary Brahm Prakash Ayurved Charak Sansthan 
Address  Khera Dabar , Najafgarh ,South West Delhi-110073 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Rohit Mandal  Chaudhary Brahm Prakash Ayurved Charak Sansthan   Room no 222 , PG Department of Swasthavritta, Institute Block , CBPACS Khera Dadar , Najafgarh , South west Delhi 110073
South West
DELHI 
7011305749

mandalrohit25@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC CBPACS  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Immuno Modulation  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: Haritaki, Reference: The Ayurvedic pharmacopeia of india, Route: Oral, Dosage Form: Churna/ Powder, Dose: 3(g), Frequency: od, Bhaishajya Kal: Abhakta, Duration: 2 Months, anupAna/sahapAna: Yes(details: Gud-), Additional Information: -none
2Comparator Arm (Non Ayurveda)-PlaceboRoasted wheat flour , Dose 3gm , Duration 2 months
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  30.00 Year(s)
Gender  Both 
Details  1.Healthy volunteers of either sex in age group 18-30 year
2.Participants willing to give a written consent 
 
ExclusionCriteria 
Details  1. Patients with concurrent Hepatic Dysfunction or Renal Dysfunction ,uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Neurological disorders, endocrine disorders, etc.) or known cases of malignancy.
2. Contraindications of haritaki mention in charak Samhita and bhavprakash
3. Women who are planning for conception / pregnant or lactating.
4. Patients suffering from Psychosis/depressive illness
5. History of hypersensitivity to any of the trial drugs or their ingredients.
6. Patient taking participation in any other clinical trial. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Changes from baseline measurements in IgG antibody investigation  0th , 61st day 
 
Secondary Outcome  
Outcome  TimePoints 
Changes in WHO quality of life scale
 
0th , 20th , 40th, 61st day 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   10/04/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

The study is randomized control trial to compare the effect of Haritaki with  Gud in Greeshma Ritu as a immunomodulator and other group with placebo. In one group Haritaki(3gm) with Gud(6gm) will be given daily early morning empty stomach and follow up on 0th , 20th , 40th , 61st day will be done. In another group , placebo (Roasted wheat flour) in 3gm dose is given and follow up done on 0th , 20th , 40th , 61st day . The trial will be conducted in Ch. brahm prakash ayurved charak sansthan with outcome i.e taking Ritu Haritaki in Greeshma Ritu has an immunomodulatory effect and Changes from baseline measurements in IgG antibody investigation will be seen .

 
Close